| Literature DB >> 35022005 |
Maria DeYoreo1, Carolyn M Rutter2, Jonathan Ozik3, Nicholson Collier3.
Abstract
BACKGROUND: Microsimulation models are mathematical models that simulate event histories for individual members of a population. They are useful for policy decisions because they simulate a large number of individuals from an idealized population, with features that change over time, and the resulting event histories can be summarized to describe key population-level outcomes. Model calibration is the process of incorporating evidence into the model. Calibrated models can be used to make predictions about population trends in disease outcomes and effectiveness of interventions, but calibration can be challenging and computationally expensive.Entities:
Mesh:
Year: 2022 PMID: 35022005 PMCID: PMC8756687 DOI: 10.1186/s12911-021-01726-0
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 3.298
Credible interval overlap measures, area overlap measures, standardized differences in means (SMD), and Hellinger distances based on posterior samples from the original calibrated model (), the start from scratch method for recalibration that incorporates new screen-detection rate targets () and the sequential recalibration method that starts from the original calibrated posterior samples when adding in the new target ()
| Parameter | CI | Area | SMD | Hellinger | CI | Area | SMD | Hellinger |
|---|---|---|---|---|---|---|---|---|
| Sojourn time | ||||||||
| | 0.57 | 0.14 | 1.75 | 0.70 | 0.93 | 0.88 | 0.06 | 0.07 |
| | 0.00 | 0.01 | 5.76 | 0.98 | 0.98 | 0.90 | 0.11 | 0.05 |
| | 0.04 | 0.04 | 2.76 | 0.90 | 0.96 | 0.92 | 0.02 | 0.05 |
Posterior means and 95% credible intervals of model parameters from original calibration to targets y, and from the model that is recalibrated to using a start from scratch approach as well as a sequential calibration approach
| Parameter | Original posterior | New targets (start from scratch) | New targets (sequential) |
|---|---|---|---|
| Sojourn time | |||
| | 3.72 (2.20, 4.92) | 2.38 (2.02, 3.07) | 2.42 (2.02, 3.23) |
| | 2.57 (2.27, 3.06) | 3.77 (3.35, 4.16) | 3.80 (3.36, 4.18) |
| | − 0.35 (− 0.96, 0.67) | 0.87 (0.65, 0.99) | 0.86 (0.61, 0.99) |
Refer to “The microsimulation model for colorectal cancer” section for details on model component distributions and parameters
Fig. 1Posterior distributions of sojourn time parameters from the original calibration (light blue) and the recalibrated model that is calibrated to two additional targets using the start from scratch method (purple). Prior distributions are shown in gray
Fig. 2Posterior distributions for sojourn time parameters using the start from scratch method for recalibrating the model to fit new targets (purple) and the sequential calibration approach (light blue). Prior distributions are shown in gray
Fig. 3Posterior distributions for mean sojourn time under original calibration (green), and with new targets calibrated via the start from scratch method (blue) and the sequential calibration approach (pink). The overlap between the two methods for recalibration with new targets is shown in purple
Credible interval overlap measures, area overlap measures, and standardized differences in means based on simulated calibration targets from published studies
| Calibration target | CI | Area | SMD | CI | Area | SMD |
|---|---|---|---|---|---|---|
| Pickhardt et al. [ | ||||||
| % of detected adenomas | ||||||
| | 0.80 | 0.59 | 0.11 | 0.95 | 0.92 | 0.03 |
| | 0.81 | 0.57 | 0.57 | 0.93 | 0.93 | 0.06 |
| | 0.70 | 0.33 | 1.12 | 0.96 | 0.89 | 0.06 |
| Corley et al. [ | ||||||
| Prevalence, Men 50–54 | 0.62 | 0.25 | 1.39 | 0.91 | 0.76 | 0.21 |
| Prevalence, Men 55–59 | 0.63 | 0.28 | 1.29 | 0.92 | 0.75 | 0.21 |
| Prevalence, Men 60–54 | 0.69 | 0.33 | 1.11 | 0.92 | 0.77 | 0.21 |
| Prevalence, Men 65–69 | 0.75 | 0.41 | 0.89 | 0.92 | 0.79 | 0.19 |
| Prevalence, Men 70–74 | 0.84 | 0.53 | 0.62 | 0.93 | 0.81 | 0.17 |
| Prevalence, Men 75+ | 0.85 | 0.65 | 0.41 | 0.93 | 0.84 | 0.15 |
| Prevalence, Women 50–54 | 0.65 | 0.25 | 1.33 | 0.96 | 0.92 | 0.04 |
| Prevalence, Women 55–59 | 0.62 | 0.27 | 1.30 | 0.97 | 0.89 | 0.06 |
| Prevalence, Women 60–54 | 0.64 | 0.32 | 1.18 | 0.98 | 0.90 | 0.07 |
| Prevalence, Women 65–69 | 0.69 | 0.40 | 0.96 | 0.97 | 0.92 | 0.05 |
| Prevalence, Women 70–74 | 0.79 | 0.54 | 0.69 | 0.98 | 0.93 | 0.04 |
| Prevalence, Women 75+ | 0.86 | 0.68 | 0.45 | 1.00 | 0.95 | 0.02 |
| Church [ | ||||||
| Pre-CRCs per 1000 lesions | ||||||
| [6, 10)mm | 0.65 | 0.30 | 1.39 | 0.98 | 0.92 | 0.08 |
| | 0.00 | 0.00 | 6.70 | 0.97 | 0.91 | 0.09 |
| Lieberman et al. [ | ||||||
| Pre-CRCs per 1000 lesions | ||||||
| | 0.90 | 0.73 | 0.36 | 0.96 | 0.93 | 0.07 |
| | 0.00 | 0.00 | 7.68 | 0.98 | 0.92 | 0.03 |
We compare the original calibrated model (), the start from scratch method for recalibration that incorporates new screen-detection rate targets () and the sequential recalibration method that starts from the original calibrated posterior samples when adding in the new target (). Size was reported categorically as mm, 6 to 9mm, and mm. We operationalized these categories as: [1, 5.5) mm, [5.5, 9.5) mm and mm
Credible interval overlap measures, area overlap measures, and standardized differences in means based on simulated annual incidence of clinically detected cancers in 1975–1979 (e.g., SEER calibration targets) [27]
| Clinically detected cancer incidence, 1975–1979 | CI overlap | Area overlap | SMD | CI overlap | Area overlap | SMD |
|---|---|---|---|---|---|---|
| Colon, female, 20–49 | 0.94 | 0.76 | 0.31 | 0.98 | 0.95 | 0.02 |
| Colon, female, 50–59 | 0.95 | 0.82 | 0.25 | 0.98 | 0.94 | 0.05 |
| Colon, female, 60–69 | 0.98 | 0.91 | 0.05 | 0.99 | 0.95 | 0.03 |
| Colon, female, 70–84 | 0.92 | 0.66 | 0.48 | 1.00 | 0.95 | 0.02 |
| Colon, female, 85+ | 0.92 | 0.70 | 0.44 | 0.99 | 0.92 | 0.09 |
| Colon, male, 20–49 | 0.93 | 0.76 | 0.33 | 1.00 | 0.94 | 0.03 |
| Colon, male, 50–59 | 0.96 | 0.88 | 0.16 | 0.98 | 0.91 | 0.08 |
| Colon, male, 60–69 | 0.99 | 0.92 | 0.08 | 0.97 | 0.90 | 0.12 |
| Colon, male, 70–84 | 0.90 | 0.66 | 0.47 | 0.97 | 0.89 | 0.12 |
| Colon, male, 85+ | 0.87 | 0.64 | 0.55 | 0.97 | 0.94 | 0.04 |
| Rectal, female, 20–49 | 0.89 | 0.65 | 0.55 | 1.00 | 0.94 | 0.03 |
| Rectal, female, 50–59 | 0.97 | 0.88 | 0.11 | 0.98 | 0.91 | 0.10 |
| Rectal, female, 60–69 | 0.95 | 0.78 | 0.30 | 0.98 | 0.89 | 0.14 |
| Rectal, female, 70–84 | 0.93 | 0.65 | 0.52 | 0.98 | 0.89 | 0.14 |
| Rectal, female, 85+ | 0.91 | 0.73 | 0.38 | 0.96 | 0.93 | 0.09 |
| Rectal, male, 20–49 | 0.98 | 0.91 | 0.10 | 0.98 | 0.93 | 0.06 |
| Rectal, male, 50–59 | 0.84 | 0.49 | 0.86 | 0.99 | 0.94 | 0.05 |
| Rectal, male, 60–69 | 0.86 | 0.53 | 0.79 | 0.98 | 0.94 | 0.07 |
| Rectal, male, 70–84 | 0.93 | 0.77 | 0.34 | 0.99 | 0.92 | 0.10 |
| Rectal, male, 85+ | 0.97 | 0.92 | 0.03 | 0.98 | 0.92 | 0.07 |
We compare the original calibrated model (), the start from scratch method for recalibration that incorporates new screen-detection rate target () and the sequential recalibration method that starts from the original calibrated posterior samples when adding in the new target ()
Posterior means and 95% credible intervals of model parameters from original calibration to targets y, and from the model that is recalibrated to using a start from scratch approach as well as a sequential calibration approach
| Parameter | Original posterior | New targets (start from scratch) | New targets (sequential) |
|---|---|---|---|
| Adenoma risk | |||
| | − 6.56 (− 6.89, − 6.11) | − 6.49 (− 6.76, − 6.10) | − 6.47 (− 6.72, − 6.11) |
| | − 0.62 (− 0.70, − 0.49) | − 0.65 (− 0.70, − 0.56) | − 0.66 (− 0.70, − 0.60) |
| | 1.62 (1.43, 1.74) | 1.69 (1.59, 1.75) | 1.69 (1.57, 1.75) |
| | 0.04 (0.03, 0.05) | 0.04 (0.04, 0.05) | 0.04 (0.04, 0.05) |
| | 0.04 (0.02, 0.05) | 0.03 (0.02, 0.05) | 0.03 (0.01, 0.05) |
| | 0.02 (− 0.01, 0.05) | 0.01 (− 0.01, 0.04) | 0.01 (− 0.01, 0.04) |
| | 0.00 (− 0.02, 0.02) | 0.00 (− 0.02, 0.03) | 0.00 (− 0.02, 0.03) |
| Adenoma growth | |||
| | 37.67 (34.02, 39.86) | 35.34 (31.96, 38.79) | 35.42 (32.26, 38.75) |
| | 1.43 (1.162, 1.701) | 1.59 (1.31, 1.83) | 1.58 (1.31, 1.81) |
| | 15.28 (11.81, 19.53) | 14.17 (11.29, 18.14) | 14.14 (11.30, 17.82) |
| | 3.39 (1.97, 4.76) | 3.24 (1.80, 4.82) | 3.39 (1.85, 4.83) |
| | 0.69 (0.56, 0.83) | 0.79 (0.65, 0.92) | 0.79 (0.66, 0.92) |
| Transition to preclinical CRC | |||
| | 3.16 (3.03, 3.35) | 3.17 (3.08, 3.26) | 3.17 (3.10, 3.26) |
| | − 0.13 (− 0.19, − 0.07) | − 0.13 (− 0.18, − 0.08) | − 0.13 (− 0.18, − 0.09) |
| | − 0.05 (− 0.24, 0.13) | − 0.04 (− 0.25, 0.14) | − 0.04 (− 0.23, 0.13) |
| | 0.07 (− 0.03, 0.17) | 0.11 (0.01, 0.20) | 0.10 (0.01, 0.19) |
| | − 1.11 (− 1.42, − 0.79) | − 0.74 (− 1.08, − 0.37) | − 0.75 (− 1.07, − 0.41) |
| | 0.12 (0.01, 0.23) | 0.10 (0, 0.23) | 0.10 (− 0.001, 0.23) |
| | 0.56 (0.50, 0.65) | 0.52 (0.50, 0.55) | 0.52 (0.50, 0.56) |
| Sojourn time | |||
| | 3.72 (2.20, 4.92) | 2.38 (2.02, 3.07) | 2.42 (2.02, 3.23) |
| | 2.57 (2.27, 3.06) | 3.77 (3.35, 4.16) | 3.80 (3.36, 4.18) |
| | − 0.35 (− 0.96, 0.67) | 0.87 (0.65, 0.99) | 0.86 (0.61, 0.99) |
Refer to “The microsimulation model for colorectal cancer” section for details on model component distributions and parameters
Credible interval overlap measures, area overlap measures, standardized differences in means (SMD), and Hellinger distances based on posterior samples from the original calibrated model (), the start from scratch method for recalibration that incorporates new screen-detection rate targets () and the sequential recalibration method that starts from the original calibrated posterior samples when adding in the new target ()
| Parameter | CI overlap | Area overlap | SMD | Hellinger | CI overlap | Area overlap | SMD | Hellinger |
|---|---|---|---|---|---|---|---|---|
| Adenoma risk | ||||||||
| | 0.91 | 0.69 | 0.35 | 0.21 | 0.97 | 0.86 | 0.07 | 0.08 |
| | 0.83 | 0.58 | 0.57 | 0.24 | 0.86 | 0.73 | 0.24 | 0.16 |
| | 0.72 | 0.41 | 0.87 | 0.40 | 0.95 | 0.93 | 0.04 | 0.05 |
| | 0.97 | 0.90 | 0.11 | 0.07 | 0.98 | 0.94 | 0.04 | 0.03 |
| | 0.90 | 0.68 | 0.51 | 0.17 | 0.98 | 0.94 | 0.04 | 0.03 |
| | 0.92 | 0.54 | 0.71 | 0.24 | 0.99 | 0.91 | 0.08 | 0.04 |
| | 0.93 | 0.70 | 0.44 | 0.16 | 1.00 | 0.92 | 0.09 | 0.03 |
| Adenoma growth | ||||||||
| | 0.76 | 0.32 | 1.47 | 0.45 | 0.97 | 0.92 | 0.05 | 0.04 |
| | 0.75 | 0.39 | 1.18 | 0.40 | 0.98 | 0.88 | 0.12 | 0.06 |
| | 0.87 | 0.61 | 0.57 | 0.21 | 0.98 | 0.95 | 0.01 | 0.04 |
| | 0.96 | 0.81 | 0.20 | 0.10 | 0.99 | 0.85 | 0.20 | 0.07 |
| | 0.66 | 0.31 | 1.44 | 0.48 | 0.97 | 0.93 | 0.01 | 0.05 |
| Transition to Pre CRC | ||||||||
| | 0.78 | 0.55 | 0.06 | 0.29 | 0.96 | 0.90 | 0.05 | 0.06 |
| | 0.88 | 0.77 | 0.05 | 0.14 | 0.97 | 0.92 | 0.03 | 0.05 |
| | 0.99 | 0.87 | 0.11 | 0.06 | 0.97 | 0.92 | 0.03 | 0.05 |
| | 0.83 | 0.57 | 0.70 | 0.25 | 0.97 | 0.84 | 0.19 | 0.08 |
| | 0.44 | 0.18 | 2.24 | 0.66 | 0.96 | 0.90 | 0.04 | 0.05 |
| | 0.97 | 0.74 | 0.34 | 0.13 | 0.99 | 0.92 | 0.08 | 0.04 |
| | 0.63 | 0.29 | 1.11 | 0.57 | 0.94 | 0.86 | 0.07 | 0.08 |
| Sojourn time | ||||||||
| | 0.57 | 0.14 | 1.75 | 0.70 | 0.93 | 0.88 | 0.06 | 0.07 |
| | 0.00 | 0.01 | 5.76 | 0.98 | 0.98 | 0.90 | 0.11 | 0.05 |
| | 0.04 | 0.04 | 2.76 | 0.90 | 0.96 | 0.92 | 0.02 | 0.05 |